MedTrace Logo

Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus

NCT01547104 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-04-11

No results posted yet for this study

Summary

The goal of this mechanistic study is to investigate the effect of Linagliptin in comparison to Glimepiride as add on therapy on several parameters characterizing postprandial metabolism and oxidative stress in type 2 diabetic patients on stable control with metformin.

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

Linagliptin

Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy

DRUG

Glimepiride

Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy

Sponsors & Collaborators

  • ikfe-CRO GmbH

    collaborator INDUSTRY

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Marcus Borchert

    lead INDUSTRY

Principal Investigators

  • Thomas Forst, MD, PhD · Ikfe GmbH

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01547104 on ClinicalTrials.gov